|
Determining viability of using APNG status as a prognostic marker in patients with glioblastoma multiforme. |
|
|
Travel, Accommodations, Expenses - Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Kristian Lindstroem Jensen |
No Relationships to Disclose |
|
|
|
|
Research Funding - Agilent |
Patents, Royalties, Other Intellectual Property - Agilent |
|
|
Employment - Agilent; DAKO |
Patents, Royalties, Other Intellectual Property - XSpray Microparticles AB |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Bjarne Winther Kristensen |
Research Funding - Agilent |
Patents, Royalties, Other Intellectual Property - DAKO |